HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Tiffany Charmet 1 Laura Schaeffer 1 Rebecca Grant 1, 2 Simon Galmiche 1 Olivia Chény 3 Cassandre von Platen 3 Alexandra Maurizot 4 Alexandra Rogoff 4 Faïza Omar 5 Christophe David 5 Alexandra Septfons 6 Simon Cauchemez 7 Alexandre Gaymard 8, 9 Bruno Lina 8, 9 Louise Lefrancois 10, 11 Vincent Enouf 10, 11, 12 Sylvie van der Werf 10, 11 Alexandra Mailles 6 Daniel Levy-Bruhl 6 Fabrice Carrat 13 Arnaud Fontanet 1, *
Abstract : Background We aimed to assess the effectiveness of two doses of mRNA COVID-19 vaccines against COVID-19 with the original virus and other lineages circulating in France. Methods In this nationwide case-control study, cases were SARS-CoV-2 infected adults with onset of symptoms between 14 February and 3 May 2021. Controls were non-infected adults from a national representative panel matched to cases by age, sex, region, population density and calendar week. Participants completed an online questionnaire on recent activity-related exposures and vaccination history. Information about the infecting virus was based on a screening RT-PCR for either B.1.1.7 or B.1.351/P.1 variants. Findings Included in our analysis were 7 288 adults infected with the original SARS-CoV-2 virus, 31 313 with the B.1.1.7 lineage, 2 550 with B.1.351/P1 lineages, and 3 644 controls. In multivariable analysis, the vaccine effectiveness (95% confidence interval) seven days after the second dose of mRNA vaccine was estimated at 88% (81-92), 86% (81-90) and 77% (63-86) against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively. Recent (2 to 6 months) history of virologically confirmed SARS-CoV-2 infection was found to be 83% (76-88), 88% (85-91) and 83% (71-90) protective against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively; and more distant (> 6 months) infections were 76% (54-87), 84% (75-90), and 74% (41-89) protective against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively. Interpretation In real-life settings, two doses of mRNA vaccines proved to be effective against COVID-19 with the original virus, B.1.1.7 lineage and B.1.351/P.1 lineages.
Document type :
Journal articles
Complete list of metadata

https://hal.sorbonne-universite.fr/hal-03292779
Contributor : Hal Sorbonne Université 5 Gestionnaire Connect in order to contact the contributor
Submitted on : Tuesday, July 20, 2021 - 3:44:41 PM
Last modification on : Thursday, April 14, 2022 - 5:26:01 PM
Long-term archiving on: : Thursday, October 21, 2021 - 6:53:00 PM

File

1-s2.0-S2666776221001484-main....
Publication funded by an institution

Licence


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

Identifiers

Citation

Tiffany Charmet, Laura Schaeffer, Rebecca Grant, Simon Galmiche, Olivia Chény, et al.. Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. The Lancet Regional Health - Europe, Elsevier, 2021, 8, pp.100171. ⟨10.1016/j.lanepe.2021.100171⟩. ⟨hal-03292779⟩

Share

Metrics

Record views

149

Files downloads

51